Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Ligand Pharmaceuticals Inc - Key Facts

Ligand Pharmaceuticals Inc - Key Employees

Ligand Pharmaceuticals Inc - Key Employee Biographies

Ligand Pharmaceuticals Inc - Major Products and Services

Ligand Pharmaceuticals Inc - History

Ligand Pharmaceuticals Inc - Company Statement

Ligand Pharmaceuticals Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Ligand Pharmaceuticals Inc - Business Description

Ligand Pharmaceuticals Inc - Corporate Strategy

Ligand Pharmaceuticals Inc - SWOT Analysis

SWOT Analysis - Overview

Ligand Pharmaceuticals Inc - Strengths

Ligand Pharmaceuticals Inc - Weaknesses

Ligand Pharmaceuticals Inc - Opportunities

Ligand Pharmaceuticals Inc - Threats

Ligand Pharmaceuticals Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Ligand Pharmaceuticals Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 02, 2019: Ligand reports first quarter 2019 financial results

Mar 12, 2019: Ligand provides highlights from Analyst Day Event

Mar 06, 2019: Ligand divests Promacta rights to Royalty Pharma for $827m

Feb 07, 2019: Ligand announces OmniAb partnership with Genagon Therapeutics

Feb 07, 2019: Ligand reports fourth quarter and full year 2018 financial results

Dec 18, 2018: Ligand introduces 2019 financial outlook and raises 2018 financial guidance

Nov 08, 2018: Ligand reports third quarter 2018 financial results

Aug 06, 2018: Ligand reports second quarter 2018 financial results

Jul 27, 2018: Fr. Emmanuel Lemelson Responds to SEC Charges

May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing prescription drug approvals. Its technologies and research capabilities contributed the development of a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc Key Recent Developments

May 02,2019: Ligand reports first quarter 2019 financial results
Mar 12,2019: Ligand provides highlights from Analyst Day Event
Mar 06,2019: Ligand divests Promacta rights to Royalty Pharma for $827m
Feb 07,2019: Ligand announces OmniAb partnership with Genagon Therapeutics
Feb 07,2019: Ligand reports fourth quarter and full year 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company